At 3:00 p.m. on April 17 U.S. time, a national multicenter clinical study led by the Guangdong Lung Cancer Institute of our hospital on the treatment of advanced lung cancer with an innovative drug KRASG12C inhibitor IBI351 (GFH925) independently developed and produced in China was invited to make a report at the 2023 annual meeting of the American Association for Cancer Research (AACR). This study was led by Prof. Wu Yilong as the national leading PI, and Prof. Zhou Qing as the leading unit PI. Dr. Xu Chongrui, who made the report on behalf of the research team, stated that the research findings showed that among lung cancer patients with the specific KRASG12C mutation, the effective rate of IBI351 (GFH925) monotherapy reached 66.7%, and the disease control rate was as high as 96.7%!

KRAS mutations are important driving gene mutations in non-small cell lung cancer, with an incidence of about 13% globally and about 5% in China. Due to the special spatial structure of KRAS mutations, drugs developed for this target have failed for decades, and for KRAS, known as a “non-druggable” target, no approved targeted treatment drug is available in China. Prof. Wu Yilong from our hospital led the national multicenter Phase I/II clinical trials of IBI351 (GFH925) in the treatment of KRASG12C mutant advanced solid tumors. The study included 74 patients with the KRASG12C mutation in advanced solid tumors. Among the 67 evaluable patients of non-small cell lung cancer, the effective rate reached 61.2%, the disease control rate reached 92.5%, and the vast majority of the relieved patients were still under ongoing treatment. The recommended dose of 600mg BID in Phase II showed better efficacy: The effective rate reached 66.7%, the disease control rate reached 96.7%, and overall safety was good.

The team from the Guangdong Lung Cancer Research Institute will continue to conduct clinical research on IBI351 (GFH925), and further deepen the research findings in order to change the therapeutic pattern of the KRASG12C mutation in advanced lung cancer diagnosis and treatment, and bring hope to more lung cancer patients with innovative Chinese drugs.

Zhang Yichen

April 23, 2023